Dermatologists Drs. Doris Day and Mark Lebwohl took home top awards at the American Skin Association’s (ASA) annual gala, which was held virtually this year.

Dr. Day, a clinical associate professor of dermatology at NYU Langone Medical Center, received ASA's Excellence in Dermatology Mentorship Award for her deep involvement and dedication to mentoring the next generation of dermatologists. "I am so proud to receive this mentorship award from ASA! My many years of work with future dermatologists is very close to my heart and I am so appreciative of this recognition," she said.

Dr Lebwohl, the Waldman Professor and Chair of the Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai, recieved ASA's Distinguished Leadership Award. "I am honored to accept this leadership award from ASA and look forward to continuing work with ASA towards their vital mission," he said. 

Incyte, a global biopharmaceutical company, was awarded ASA's Global Impact Award in Biopharmaceutical Research and Medicine. The award was accepted by Dr. Jim Lee, Group Vice President, Head of Inflammation and Autoimmunity. The company's research and development team is exploring the potential of JAK inhibition in a number of immune-mediated dermatologic conditions with a high unmet medical need, including atopic dermatitis, vitiligo and hidradenitis suppurativa. 

Pfizer, Inc. was presented with ASA's Distinguished Corporate Leadership Award for delivering some of the most important medical innovations in history over the last 170 years. Pfizer's award was accepted by Ehab Mahgoub, MD, MSc, Vice President of North America Medical Affairs, Inflammation & Immunology. "Pfizer is honored to receive this award, which further reinforces the importance of collaboration in the medical dermatology community. We are dedicated to developing breakthroughs that help with the day-to-day suffering experienced by people living with chronic inflammatory skin diseases," he said. The award honored the company's foundation in biotechnology with 25,000 clinical researchers testing every day, focusing on pharmaceutical development and innovation.

 "ASA is proud to honor Dr. Doris Day, Dr. Mark Lebwohl, Incyte and Pfizer for their innovative efforts in the field of dermatology, and for their exceptional commitment to medical advancement. The important work of our honorees continues to help further ASA's mission of finding cures for melanoma, skin cancer and other skin diseases," said Howard P. Milstein, Chairman of ASA.

President of ASA, Dr. David Norris, agreed: "I am proud of ASA's ongoing work and congratulate these much-deserving honorees, Dr. Day, Dr. Lebwohl, Incyte and Pfizer, Inc. on their awards."